- Baxter International Inc (NYSE: BAX) posted Q4 revenue of $3.89 billion, which beat the consensus of $3.77 billion, up 11% Y/Y on a reported basis, 17% on a constant currency, and 2% on an operational basis.
- Adjusted EPS of $0.88 came in below the consensus of $0.94.
- Advanced Surgery and Clinical Nutrition delivered mid-to-high single-digit growth at constant currency rates, reflecting solid demand across both product categories.
- Renal Care delivered low single-digit growth at constant rates, driven by mid-single-digit growth of peritoneal dialysis therapies offset by low single-digit declines in in-center hemodialysis therapies.
- Double-digit growth at constant rates in BioPharma Solutions (BPS) reflected strong demand for non-COVID-related services, which more than offset lower COVID-19 vaccine manufacturing revenues.
- The Deerfield, Illinois-based company is executing a cost reduction program in parallel with its operating model redesign that is expected to be finalized later this quarter.
- This initiative is expected to deliver more than $300 million in savings during 2023 and expect to result in a global workforce reduction of less than 5%.
- Related: Baxter Plans Divesting Renal Care Business Into Separate Public Company, Shares Fall.
- Outlook: Baxter expects FY23 adjusted EPS of $2.75-$2.95 vs. consensus of $3.56. For Q1 FY23, the company forecasts $0.46-$0.50 Vs. $0.76 estimate.
- Price Action: BAX shares are down 8.17% at $41.95 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
